Network Pharmacology Analysis and Molecular Docking to Unveil the Potential Mechanisms of San-Huang-Chai-Zhu Formula Treating Cholestasis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Feb 23

PMID 35196362

Authors

Binbin Liu

Jie Zhang

Lu Shao

Jiaming Yao

Affiliations

Soon will be listed here.

Abstract

Objective: Chinese medicine formulae possess the potential for cholestasis treatment. This study aimed to explore the underlying mechanisms of San-Huang-Chai-Zhu formula (SHCZF) against cholestasis.

Methods: The major chemical compounds of SHCZF were identified by high-performance liquid chromatography. The bioactive compounds and targets of SHCZF, and cholestasis-related targets were obtained from public databases. Intersected targets of SHCZF and cholestasis were visualized by Venn diagram. The protein-protein interaction and compound-target networks were established by Cytoscape according to the STRING database. The biological functions and pathways of potential targets were characterized by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis. The biological process-target-pathway network was constructed by Cytoscape. Finally, the interactions between biological compounds and hub target proteins were validated via molecular docking.

Results: There 7 major chemical compounds in SHCZF. A total of 141 bioactive compounds and 83 potential targets were screened for SHCZF against cholestasis. The process of SHCZF against cholestasis was mainly involved in AGE-RAGE signaling pathway in diabetic complications, fluid shear stress and atherosclerosis, and drug metabolism-cytochrome P450. ALB, IL6, AKT1, TP53, TNF, MAPK3, APOE, IL1B, PPARG, and PPARA were the top 10 hub targets. Molecular docking showed that bioactive compounds of SHCZF had a good binding affinity with hub targets.

Conclusions: This study predicted that the mechanisms of SHCZF against cholestasis mainly involved in AGE-RAGE signaling pathway in diabetic complications, fluid shear stress and atherosclerosis, and drug metabolism-cytochrome P450. Moreover, APOE, AKT1, and TP53 were the critical hub targets for bioactive compounds of SHCZF.

Citing Articles

Exploring the Potential Mechanisms of Action of Hemsl. Extract in the Treatment of Cholestasis using UPLC-MS/MS, Systematic Network Pharmacology, and Molecular Docking.

Wang Y, Tan N, Su R, Liu Z, Hu N, Dong Q Comb Chem High Throughput Screen. 2024; 27(13):1948-1968.

PMID: 38357941 DOI: 10.2174/0113862073275657231210055250.

The Mechanism of Plantaginis Semen in the Treatment of Diabetic Nephropathy based on Network Pharmacology and Molecular Docking Technology.

He L, Shen K, He L, Chen Y, Tang Z Endocr Metab Immune Disord Drug Targets. 2023; 24(3):363-379.

PMID: 37718520 DOI: 10.2174/1871530323666230915100355.

The IDI1/SREBP2 axis drives intrahepatic cholestasis and is a treatment target of San-Huang-Cai-Zhu formula identified by sequencing and experiments.

Yan J, Nie Y, Chen Z, Yao J, Zhang S, Chen Z Front Pharmacol. 2023; 14:1093934.

PMID: 36843951 PMC: 9944032. DOI: 10.3389/fphar.2023.1093934.

References

Yang X, Feng Y, Liu Y, Ye X, Ji X, Sun L . Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine. 2021; 87:153575. DOI: 10.1016/j.phymed.2021.153575. View

Rappaport N, Twik M, Plaschkes I, Nudel R, Iny Stein T, Levitt J . MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Res. 2016; 45(D1):D877-D887. PMC: 5210521. DOI: 10.1093/nar/gkw1012. View

Chin C, Chen S, Wu H, Ho C, Ko M, Lin C . cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8 Suppl 4:S11. PMC: 4290687. DOI: 10.1186/1752-0509-8-S4-S11. View

Zhang R, Zhu X, Bai H, Ning K . Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment. Front Pharmacol. 2019; 10:123. PMC: 6393382. DOI: 10.3389/fphar.2019.00123. View

Xiao L, Zhang F, Zhao Y, Zhang L, Xie Z, Huang K . Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury. Sci Rep. 2020; 10(1):18128. PMC: 7582878. DOI: 10.1038/s41598-020-75141-2. View

Su G, Wang H, Bai J, Chen G, Pei Y . A Metabonomics Approach to Drug Toxicology in Liver Disease and its Application in Traditional Chinese Medicine. Curr Drug Metab. 2019; 20(4):292-300. DOI: 10.2174/1389200220666181231124439. View

Wei F, Liu H, Fan Y, Li X, Zhao S, Qin X . [Mechanism of Xiaoyao San in treatment of depression,breast hyperplasia,and functional dyspepsia based on network pharmacology]. Zhongguo Zhong Yao Za Zhi. 2021; 46(16):4230-4237. DOI: 10.19540/j.cnki.cjcmm.20210520.702. View

Ma J, Wang J, Ghoraie L, Men X, Haibe-Kains B, Dai P . A Comparative Study of Cluster Detection Algorithms in Protein-Protein Interaction for Drug Target Discovery and Drug Repurposing. Front Pharmacol. 2019; 10:109. PMC: 6389713. DOI: 10.3389/fphar.2019.00109. View

Sterling T, Irwin J . ZINC 15--Ligand Discovery for Everyone. J Chem Inf Model. 2015; 55(11):2324-37. PMC: 4658288. DOI: 10.1021/acs.jcim.5b00559. View

10.

Guan L, Yang H, Cai Y, Sun L, Di P, Li W . ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness. Medchemcomm. 2019; 10(1):148-157. PMC: 6350845. DOI: 10.1039/c8md00472b. View

11.

Hu N, Liu J, Xue X, Li Y . The effect of emodin on liver disease -- comprehensive advances in molecular mechanisms. Eur J Pharmacol. 2020; 882:173269. DOI: 10.1016/j.ejphar.2020.173269. View

12.

Szklarczyk D, Santos A, von Mering C, Jensen L, Bork P, Kuhn M . STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2015; 44(D1):D380-4. PMC: 4702904. DOI: 10.1093/nar/gkv1277. View

13.

Zhang H, Wu W, Li F, Song W, He Y, Yang M . [Study on liver protection, cholagogic effect and hepatotoxicity of Gardeniae fructus]. Zhongguo Zhong Yao Za Zhi. 2012; 36(19):2610-4. View

14.

Pan L, Li Z, Wang Y, Zhang B, Liu G, Liu J . Network pharmacology and metabolomics study on the intervention of traditional Chinese medicine Huanglian Decoction in rats with type 2 diabetes mellitus. J Ethnopharmacol. 2020; 258:112842. DOI: 10.1016/j.jep.2020.112842. View

15.

Stelzer G, Plaschkes I, Oz-Levi D, Alkelai A, Olender T, Zimmerman S . VarElect: the phenotype-based variation prioritizer of the GeneCards Suite. BMC Genomics. 2016; 17 Suppl 2:444. PMC: 4928145. DOI: 10.1186/s12864-016-2722-2. View

16.

Fury W, Batliwalla F, Gregersen P, Li W . Overlapping probabilities of top ranking gene lists, hypergeometric distribution, and stringency of gene selection criterion. Conf Proc IEEE Eng Med Biol Soc. 2007; 2006:5531-4. DOI: 10.1109/IEMBS.2006.260828. View

17.

Zhou Y, Wu R, Cai F, Zhou W, Lu Y, Zhang H . Xiaoyaosan decoction alleviated rat liver fibrosis via the TGFβ/Smad and Akt/FoxO3 signaling pathways based on network pharmacology analysis. J Ethnopharmacol. 2020; 264:113021. DOI: 10.1016/j.jep.2020.113021. View

18.

Jungst C, Berg T, Cheng J, Green R, Jia J, Mason A . Intrahepatic cholestasis in common chronic liver diseases. Eur J Clin Invest. 2013; 43(10):1069-83. DOI: 10.1111/eci.12128. View

19.

Seeliger D, de Groot B . Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010; 24(5):417-22. PMC: 2881210. DOI: 10.1007/s10822-010-9352-6. View

20.

Amberger J, Hamosh A . Searching Online Mendelian Inheritance in Man (OMIM): A Knowledgebase of Human Genes and Genetic Phenotypes. Curr Protoc Bioinformatics. 2017; 58:1.2.1-1.2.12. PMC: 5662200. DOI: 10.1002/cpbi.27. View